Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395629 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00395629 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT00395629, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.
Interventions
- DRUG Deferasirox (ICL670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395629
The ClinicalTrials.gov registry entry for NCT00395629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox (ICL670) is the first listed.
NCT00395629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395629 about?
NCT00395629 is a clinical study titled "Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis". Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.
What is the current status of trial NCT00395629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2006-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00395629?
The interventions under investigation include: Deferasirox (ICL670) (DRUG).
Who is sponsoring clinical trial NCT00395629?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.